Ebright et al. 2020 (PRJNA601135)
General Details
Title | Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis [ribo-Seq BRx142] |
---|---|
Organism | |
Number of Samples | 16 |
Release Date | 2020/01/14 00:00 |
Sequencing Types | |
Protocol Details |
Study Links
GWIPS-viz | Trips-Viz |
---|---|
Repository Details
SRA | SRP241899 |
---|---|
ENA | SRP241899 |
GEO | GSE143623 |
BioProject | PRJNA601135 |
Publication
Title | |
---|---|
Authors | Ebright RY,Lee S,Wittner BS,Niederhoffer KL,Nicholson BT,Bardia A,Truesdell S,Wiley DF,Wesley B,Li S,Mai A,Aceto N,Vincent-Jordan N,Szabolcs A,Chirn B,Kreuzer J,Comaills V,Kalinich M,Haas W,Ting DT,Toner M,Vasudevan S,Haber DA,Maheswaran S,Micalizzi DS |
Journal | Science (New York, N.Y.) |
Publication Date | 2020 Mar 27 |
Abstract | Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors, but only a small subset of these cells generates metastases. We conducted an in vivo genome-wide CRISPR activation screen in CTCs from breast cancer patients to identify genes that promote distant metastasis in mice. Genes coding for ribosomal proteins and regulators of translation were enriched in this screen. Overexpression of RPL15 , which encodes a component of the large ribosomal subunit, increased metastatic growth in multiple organs and selectively enhanced translation of other ribosomal proteins and cell cycle regulators. RNA sequencing of freshly isolated CTCs from breast cancer patients revealed a subset with strong ribosome and protein synthesis signatures; these CTCs expressed proliferation and epithelial markers and correlated with poor clinical outcome. Therapies targeting this aggressive subset of CTCs may merit exploration as potential suppressors of metastatic progression. Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. |
PMC | PMC7307008 |
PMID | 32029688 |
DOI |
Run Accession | Study Accession | Scientific Name | Cell Line | Library Type | Treatment | GWIPS-viz | Trips-Viz | Reads | BAM | BigWig (F) | BigWig (R) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SRR10883784 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883785 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883786 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883787 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883788 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883789 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883790 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883791 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883792 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883793 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883794 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883795 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883796 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883797 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883798 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
SRR10883799 | PRJNA601135 | Homo sapiens | CTC | Ribo-Seq | Cycloheximide | ||||||||
Run Accession | Study Accession | Scientific Name | Cell Line | Library Type | Treatment | GWIPS-viz | Trips-Viz | Reads | BAM | BigWig (F) | BigWig (R) |
ⓘ For more Information on the columns shown here see: About